NCT02570997View on ClinicalTrials.gov

Ascending Dose Study of CT1812 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

May 31, 2016

Conditions
Cognitive Impairment
Interventions
DRUG

CT1812

Doses will be escalated in the following sequence: 10mg, 30mg, 90mg, 180mg, 360mg, 650mg.

DRUG

Placebo

Matching placebo administered.

Trial Locations (1)

3004

Nucleus Network Limited, Melbourne

Sponsors
All Listed Sponsors
lead

Cognition Therapeutics

INDUSTRY

NCT02570997 - Ascending Dose Study of CT1812 in Healthy Volunteers | Biotech Hunter | Biotech Hunter